Global Hemp Group Signs Binding LOI with Apollon Formularies plc

GHG has acquired the exclusive perpetual license for North America to certain Apollon Intellectual Property and proprietary technology, including four key patents along with any and all associated preclinical and clinical data relating to the patents and proprietary technology.

Apollon Formularies Plc. is a UK-based international pharmaceutical company developing cancer treatments from natural biologics, including medical cannabis, functional mushrooms, psychedelic mushrooms and combinations of these compounds, which to date have shown successful independent, third-party results in preclinical testing. Apollon utilizes an artificial intelligence-based drug discovery platform.

The Company has also been granted a 60-day option to conduct due diligence, following which it may exercise its option to acquire the entirety of Apollon’s global assets.